In This Article:
As global markets continue to reach new highs, buoyed by optimism over potential trade deals and advancements in artificial intelligence infrastructure, growth stocks have notably outperformed their value counterparts. In this environment of heightened investor confidence, companies with high insider ownership often attract attention due to the perceived alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
| Duc Giang Chemicals Group (HOSE:DGC) | 31.4% | 25.7% |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Laopu Gold (SEHK:6181) | 36.4% | 36.6% |
| Medley (TSE:4480) | 34.1% | 27.3% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
| HANA Micron (KOSDAQ:A067310) | 18.2% | 119.4% |
Here's a peek at a few of the choices from the screener.
Sectra
Simply Wall St Growth Rating: ★★★★★☆
Overview: Sectra AB (publ) offers solutions in medical IT and cybersecurity across Sweden, the United Kingdom, the Netherlands, and other parts of Europe, with a market cap of SEK48.30 billion.
Operations: The company's revenue is primarily derived from its Imaging IT Solutions segment, which generated SEK2.61 billion, followed by Secure Communications at SEK425.85 million and Business Innovation at SEK85.07 million.
Insider Ownership: 30.3%
Sectra's earnings are forecast to grow significantly at 27.9% annually, outpacing the Swedish market. Despite recent declines in quarterly revenue and net income, Sectra has secured strategic contracts with major healthcare providers like Helse Nord RHF and UZ Leuven for its enterprise imaging solutions. These agreements highlight Sectra's innovative digital pathology offerings that enhance diagnostic efficiency and patient care, supporting its growth trajectory amidst high insider ownership stability.
Xiamen Yan Palace Bird's Nest Industry
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Xiamen Yan Palace Bird's Nest Industry Co., Ltd. operates in the research, development, production, and marketing of edible bird’s nest products in China, with a market cap of HK$3.96 billion.
Operations: The company's revenue segments include CN¥21.07 million from sales to online distributors, CN¥508.94 million from sales to offline distributors, CN¥907.52 million from direct sales to online customers, CN¥344.32 million from direct sales to offline customers, and CN¥290.51 million from direct sales to e-commerce platforms.